Lapatinib seems to be an adequate adjuvant treatment for HER-2-positive breast cancer, since it demonstrates effectiveness in cases of advanced and metastasized cancer, appears to have few serious side effects and may be associated with reduction of the incidence of cerebral metastasis, in addition to its easy oral administration once a day. Here, ERBB2 is linked to breast carcinoma.